Researchers at the University of California San Diego School of Medicine, in collaboration with international partners, have achieved a significant milestone in the treatment of obstructive sleep apnea (OSA). Their groundbreaking study highlights the potential of tripeptide, a drug known for managing type 2 diabetes, as an effective therapy for OSA. Let’s delve into the details:
The Challenge of Obstructive Sleep Apnea
Stay connected to UKNIP via Google News
ENJOYED THIS STORY? Choose UKNIP as a 'Preferred Source' on Google News for quick access to the news you value.
